Gene Therapy & Immunotherapy
2 articles RSS
Fate Therapeutics Wins FDA Clearance for FT839, a Dual-CAR T-Cell Therapy for Autoimmune Disease
FDA cleared the IND for FT839, an off-the-shelf CAR T-cell candidate co-targeting CD19 and CD38 across five autoimmune diseases without chemotherapy conditioning.
4 min read3 sources
Doudna-Backed Azalea Therapeutics Demonstrates Tumor Clearance With Single-Dose In Vivo CAR-T in Nature Study
A two-vector system inserts a CAR transgene at the TRAC locus inside the body, generating functional cancer-killing T cells without ex vivo manufacturing or lymphodepletion.
4 min read3 sources